In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer
Authors:
- Gregory T. WurzGWGregory T. Wurz
- Michael W. DeGregorioMDMichael W. DeGregorio
- 1 June 2001
- journal article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 77 (4-5) , 271-279
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulatorEuropean Journal of Clinical Pharmacology, 2000
- Selective Estrogen Receptor Modulators: Structure, Function, and Clinical UseJournal of Clinical Oncology, 2000
- Risk and prognosis of endometrial cancer after tamoxifen for breast cancerThe Lancet, 2000
- Selective Estrogenic Effects of a Novel Triphenylethylene Compound, FC1271a, on Bone, Cholesterol Level, and Reproductive Tissues in Intact and Ovariectomized RatsEndocrinology, 2000
- Tamoxifen Therapy for Breast Cancer and Endometrial Cancer RiskJNCI: Journal of the National Cancer Institute, 1999
- Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow cultureJournal of Cellular Biochemistry, 1999
- Clinical Effects of Raloxifene Hydrochloride in WomenAnnals of Internal Medicine, 1999
- Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancerThe Lancet, 1997
- Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy—long-term follow-up of a Swedish cohortInternational Journal of Cancer, 1996
- Biochemical and pharmacological effects of toremifene metabolitesCancer Chemotherapy and Pharmacology, 1990